2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner

BayerThe award-winner of the 2016 Otto Bayer Award has been named: the Board of Trustees of the Bayer Science & Education Foundation and the Scientific Committee for this award have presented Professor Dr. Dirk Trauner with the EUR 75,000 prize, one of Germany's most prestigious scientific accolades. The award is in recognition for his pioneering contributions in "Photopharmacology and Chemical Optogenetics". Trauner developed novel switches that can sensitize a wide variety of cellular processes toward light. His work has potential to open new chemotherapeutical treatment opportunities, including chemical treatment strategies to cure blindness and cancer. The award will be officially presented by Werner Baumann, who will become the CEO of Bayer at May 1, 2016, at a ceremony in Berlin on June 6, 2016.

The Otto Bayer Award honors scientists who have conducted pioneering research in innovative areas of chemistry and biochemistry. It has been presented since 1984 in memory of its endower Professor Dr. Otto Bayer (not related to the company founder). The long-tenured Head of Research at Bayer AG invented polyurethane chemistry. He strengthened the contact of industry and academia and supported the training of young scientist throughout his long career.

Prof. Ernst-Ludwig Winnacker, Chairman of the Board of Trustees of the Bayer Science & Education Foundation, said: "Photopharmacology is the control of small molecules by light. The precision of their effects in biological systems can be increased so fundamental that this concept has become an indispensable tool of modern cell biology research and already provides important impetus for future applications in neuroscience and cancer. Dirk Trauner is a pioneer of this technology at the interface between biology and chemistry, and therefore seems to the jury an ideal candidate for the most prestigious Otto Bayer Award."

The Otto Bayer 2016Award is being given in recognition of this innovative technology, but also on the broad objective of Trauner’s research: to demonstrate the awesome power of chemical synthesis with challenging target molecules and to use it toward the establishment of synthetic biological pathways. This work is of high value for a life science company as Bayer, where a major part of the business is to invent and produce new molecules that interact with the biochemical processes in various living species.

"Our future will be shaped by advances in basic and applied research. We want to promote science and strengthen excellence," said Kemal Malik, member of the Bayer Board of Management for Innovation and Chairman of the foundation. "Research plays a central role for the inventor company Bayer. The knowledge, acceptance and application of future technologies in the life sciences are key framework conditions in our society, and Bayer AG wants to contribute to establishing them among other means through its foundations and by awarding this prize," Malik continued.

The prize is awarded by the Bayer Science & Education Foundation. The foundation acts as initiator, promoter and partner for progress at the interface between industry, academia and civil society. The primary objectives are the recognition of frontier research, the promotion of science talents and the support for innovative school science projects. In terms of content, the activities focus on life science, health and medicine. The foundation honors frontier research achievements every two years with the Otto Bayer Award and in alternate years with the Hansen Family Award, each of which carries prize money of EUR 75,000. In addition, the foundation presents two talent awards: The international Bayer Early Excellence in Science Award in biology, chemistry and medical science, each with prize money of EUR 10,000, and the Bayer Thrombosis Research Award for basic and clinical thrombosis research with prize money of EUR 30,000.

The new Otto Bayer Award winner, Dirk Trauner was born and raised in Linz, Austria, studied biology and chemistry at the University of Vienna, and received his undergraduate degree in chemistry from the Free University, Berlin. He then pursued a PhD in chemistry under the direction of Prof. Johann Mulzer, with whom he moved to the University of Frankfurt and then back to Vienna. Following a mandatory stint in the Austrian Army, he became a postdoctoral fellow with Prof. Samuel J. Danishefsky at the Memorial Sloan-Kettering Cancer Center. After two great years in New York City, Trauner joined the Department of Chemistry at the University of California, Berkeley, where he rose through the ranks to become an Associate Professor of Chemistry (with tenure). He was also appointed as a member of the Lawrence Berkeley National Laboratory. In the summer of 2008, he moved to the University of Munich, where he currently resides as a Professor of Chemical Biology and Chemical Genetics. Despite his extensive forays into biology and physiology Trauner remains an organic chemist at heart, as evidenced by the synthesis of more than 80 natural products.

Dirk Trauner has been awarded the 2016 Emil Fischer Medal and is a Corresponding Member of the Austrian Academy of Sciences and a Fellow of the Royal Society of Chemistry. He is also the recipient of the Kitasato Medal, the Alfred P. Sloan Fellowship, an ERC Advanced Grant, and the Austrian Chemical Society Award for the best thesis in 1997. He sits on the editorial board of Natural Product Reports and the editorial advisory board of ACS Central Science, ACS Chemical Neuroscience, Cell Chemical Biology and Chem.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...